Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab vs Apheresis in Hypercholesterolemia
NCT02585895Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of evolocumab in hypercholesterolemia, sponsored by Amgen. Started Dec 2015; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02585895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585895.